Clinical outcomes of chemotherapy in patients with undifferentiated carcinoma of the pancreas: a retrospective multicenter cohort study

[1]  L. Wood,et al.  Epithelial-mesenchymal transition in undifferentiated carcinoma of the pancreas with and without osteoclast-like giant cells , 2020, Virchows Archiv.

[2]  E. Gallardo,et al.  SEOM clinical guideline thyroid cancer (2019) , 2020, Clinical and Translational Oncology.

[3]  A. Jemal,et al.  Cancer statistics, 2020 , 2020, CA: a cancer journal for clinicians.

[4]  C. V. van Eijck,et al.  Nationwide trends in incidence, treatment and survival of pancreatic ductal adenocarcinoma. , 2019, European journal of cancer.

[5]  T. H. Nguyen,et al.  The global, regional, and national burden of pancreatic cancer and its attributable risk factors in 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017 , 2019, The lancet. Gastroenterology & hepatology.

[6]  T. H. Nguyen,et al.  The global, regional, and national burden of colorectal cancer and its attributable risk factors in 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017 , 2019, The lancet. Gastroenterology & hepatology.

[7]  H. Imaoka,et al.  New Era of Endoscopic Ultrasound-Guided Tissue Acquisition: Next-Generation Sequencing by Endoscopic Ultrasound-Guided Sampling for Pancreatic Cancer , 2019, Journal of clinical medicine.

[8]  G. Sethi,et al.  Cycloastragenol can negate constitutive STAT3 activation and promote paclitaxel-induced apoptosis in human gastric cancer cells. , 2019, Phytomedicine : international journal of phytotherapy and phytopharmacology.

[9]  A. LaCasce,et al.  AIDS-Related Kaposi Sarcoma, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology. , 2019, Journal of the National Comprehensive Cancer Network : JNCCN.

[10]  G. Sethi,et al.  Oxymatrine Attenuates Tumor Growth and Deactivates STAT5 Signaling in a Lung Cancer Xenograft Model , 2019, Cancers.

[11]  S. Mori,et al.  Functional Genome-wide Screening Identifies Targets and Pathways Sensitizing Pancreatic Cancer Cells to Dasatinib , 2018, Journal of Cancer.

[12]  H. Sasano,et al.  Expression of Epithelial-Mesenchymal Transition Proteins in Pancreatic Anaplastic (Undifferentiated) Carcinoma , 2018, Pancreas.

[13]  R. Weinberg,et al.  New insights into the mechanisms of epithelial–mesenchymal transition and implications for cancer , 2018, Nature reviews. Molecular cell biology.

[14]  M. Saitoh.  Involvement of partial EMT in cancer progression. , 2018, Journal of biochemistry.

[15]  L. Diaz,et al.  386PEfficacy of pembrolizumab in phase 2 KEYNOTE-164 and KEYNOTE-158 studies of microsatellite instability high cancers , 2017 .

[16]  Masao Tanaka,et al.  Clinical outcome of elderly patients with unresectable pancreatic cancer treated with gemcitabine plus S-1, S-1 alone, or gemcitabine alone: Subgroup analysis of a randomised phase III trial, GEST study. , 2016, European journal of cancer.

[17]  T. Conroy,et al.  Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[18]  G. Ren,et al.  Epithelial-mesenchymal transition and drug resistance in breast cancer (Review). , 2015, International journal of oncology.

[19]  Birgit Funke,et al.  College of American Pathologists' laboratory standards for next-generation sequencing clinical tests. , 2015, Archives of pathology & laboratory medicine.

[20]  G. Sethi,et al.  Brassinin inhibits STAT3 signaling pathway through modulation of PIAS-3 and SOCS-3 expression and sensitizes human lung cancer xenograft in nude mice to paclitaxel , 2015, Oncotarget.

[21]  L. Poellinger,et al.  Selective inhibition of unfolded protein response induces apoptosis in pancreatic cancer cells , 2014, Oncotarget.

[22]  Khin Thway,et al.  Systemic treatment of soft-tissue sarcoma—gold standard and novel therapies , 2014, Nature Reviews Clinical Oncology.

[23]  C. Chen,et al.  Acquisition of epithelial–mesenchymal transition is associated with Skp2 expression in paclitaxel-resistant breast cancer cells , 2014, British Journal of Cancer.

[24]  David Goldstein,et al.  Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. , 2013, The New England journal of medicine.

[25]  K. Lillemoe,et al.  Pancreatic Ductal Adenocarcinoma: Is There a Survival Difference for R1 Resections Versus Locally Advanced Unresectable Tumors? What Is a “True” R0 Resection? , 2013, Annals of surgery.

[26]  G. Berx,et al.  Regulatory networks defining EMT during cancer initiation and progression , 2013, Nature Reviews Cancer.

[27]  W. Harmsen,et al.  Clinical outcomes for anaplastic pancreatic cancer: a population-based study. , 2012, Journal of the American College of Surgeons.

[28]  Laurentiu M. Pop,et al.  Pancreatic Ductal Adenocarcinoma , 2012, Journal of Investigative Medicine.

[29]  R. Hruban,et al.  Pancreatic cancer , 2011, The Lancet.

[30]  Pierre Michel,et al.  FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. , 2011, The New England journal of medicine.

[31]  Patrick Royston,et al.  Multiple imputation using chained equations: Issues and guidance for practice , 2011, Statistics in medicine.

[32]  M. Büchler,et al.  Anaplastic pancreatic cancer: Presentation, surgical management, and outcome. , 2011, Surgery.

[33]  Mariano Provencio,et al.  Screening for epidermal growth factor receptor mutations in lung cancer. , 2009, The New England journal of medicine.

[34]  M. Kenward,et al.  Multiple imputation for missing data in epidemiological and clinical research: potential and pitfalls , 2009, BMJ : British Medical Journal.

[35]  E. Nakakura,et al.  Pancreatic adenocarcinoma: Clinical Practice Guidelines in Oncology. , 2005, Journal of the National Comprehensive Cancer Network : JNCCN.

[36]  E. Paal,et al.  A clinicopathologic and immunohistochemical study of 35 anaplastic carcinomas of the pancreas with a review of the literature. , 2001, Annals of diagnostic pathology.

[37]  M. Egorin,et al.  Treatment of anaplastic thyroid carcinoma with paclitaxel: phase 2 trial using ninety-six-hour infusion. Collaborative Anaplastic Thyroid Cancer Health Intervention Trials (CATCHIT) Group. , 2000, Thyroid : official journal of the American Thyroid Association.

[38]  N. Lemoine,et al.  Undifferentiated carcinoma of the pancreas: analysis of intermediate filament profile and Ki‐ras mutations provides evidence of a ductal origin , 1998, The Journal of pathology.

[39]  J. Kissane,et al.  Pleomorphic carcinoma of the pancreas. An analysis of 15 cases , 1977, Cancer.

[40]  E. Diamandis,et al.  Pancreatic cancer. , 2013, Clinical chemistry.

[41]  Michael R Hamblin,et al.  CA : A Cancer Journal for Clinicians , 2011 .

[42]  R. Wilson,et al.  Cancer genome sequencing: a review. , 2009, Human molecular genetics.

[43]  L. Schwartz,et al.  New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.

[44]  E. Ornstein,et al.  The Potential and the Pitfalls , 2008 .

[45]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..